Publicacións en colaboración con investigadores/as de Complexo Hospitalario Universitario de Vigo (44)

2024

  1. Clinical usefulness of serum angiotensin converting enzyme in silicosis

    Pulmonology, Vol. 30, Núm. 4, pp. 370-377

  2. Cost–Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study

    Diseases, Vol. 12, Núm. 10

  3. Effectiveness and safety of pembrolizumab as first-line treatment for non-small cell lung cancer in real clinical practice

    Journal of Oncology Pharmacy Practice

2023

  1. Carbapenem alternatives for treatment of bloodstream infections due to AmpC producing enterobacterales

    Annals of Clinical Microbiology and Antimicrobials, Vol. 22, Núm. 1

  2. Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study

    American Journal of Cardiovascular Drugs, Vol. 23, Núm. 5, pp. 583-593

  3. Interleukin 18 (IL-18) and IL-3 in Extracellular Vesicles: Biomarkers for Durable Elite Control of HIV-1

    Journal of Infectious Diseases

  4. Real-world evidence of sorafenib for the treatment of hepatocellular carcinoma: A single-center study

    Journal of Cancer Research and Therapeutics, Vol. 19, Núm. 5, pp. 1345-1349

2022

  1. Ceftazidime–avibactam treatment in bacteremia caused by OXA-48 carbapenemase-producing Klebsiella pneumoniae

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 41, Núm. 9, pp. 1173-1182

  2. Cerebrospinal fluid drainage-related ventriculitis due to multidrug-resistant microorganisms

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 40, Núm. 6, pp. 322-325

  3. Massive Release of CD9+ Microvesicles in Human Immunodeficiency Virus Infection, Regardless of Virologic Control

    The Journal of infectious diseases, Vol. 225, Núm. 6, pp. 1040-1049

  4. Real-World Evidence for Treat-and-Extend Regimen of Ranibizumab Therapy for Macular Oedema Secondary to Branch Retinal Vein Occlusion

    Pharmaceuticals, Vol. 15, Núm. 1

  5. Regorafenib and trifluridine/tipiracil in real clinical practice

    Journal of cancer research and therapeutics, Vol. 18, pp. S367-S373

  6. Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: A systematic literature review

    British Journal of Clinical Pharmacology, Vol. 88, Núm. 4, pp. 1529-1550

2021

  1. Direct costs in patients with chronic inflammatory arthropathies on biological therapy: A real-world data study

    Clinical and Experimental Rheumatology, Vol. 39, Núm. 4, pp. 736-745

  2. Effectiveness, Safety, and Adherence to Treatment of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Real Practice

    Clinical Therapeutics, Vol. 43, Núm. 4, pp. e111-e121

  3. Fitofotodermatitis

    FMC: Formación Médica Continuada en Atención Primaria, Vol. 28, Núm. 10, pp. 573-575

  4. Medication persistence on biological therapies prescribed for the treatment of chronic inflammatory arthropathies: a real-world data study

    European Journal of Hospital Pharmacy, Vol. 28, Núm. e1, pp. E47-E50

  5. Mortality-related factors in patients with OXA-48 carbapenemase-producing Klebsiella pneumoniae bacteremia

    Medicine, Vol. 100, Núm. 14, pp. e24880

  6. Real-world prevalence and consequences of potential drug-drug interactions in the first-wave COVID-19 treatments

    Journal of Clinical Pharmacy and Therapeutics, Vol. 46, Núm. 3, pp. 724-730

  7. Serum levels of inflammatory mediators as prognostic biomarker in silica exposed workers

    Scientific reports, Vol. 11, Núm. 1, pp. 13348